Results 161 to 170 of about 108,133 (341)

Current and potential use of GLP-1R agonists: beyond type 2 diabetes

Revista Mexicana de Endocrinología, Metabolismo y Nutrición
Intestinal incretins, glucagon-like peptide 1 (GLP-1), and gastric insulinotropic peptide, which are released after food ingestion, have glucoregulatory effects, which is why, in recent years, pharmacological agents with an impact similar to incretins ...
Graciela Zambrano-Galván, Ángel González-Romero, Miguel A. Reyes-Romero, Abelardo Camacho-Luis   +3 more
doaj   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Trends in diabetes medication prescribing from 2018 to 2021: A cross-sectional analysis.

PLoS ONE
Several new classes of medications for diabetes have recently become available newer medication classes have been increasing in use. It is unclear how their utilization varied across provinces and how the COVID-19 pandemic may have affected these trends.
Jessica Riad, Fred Abdelmalek, Noah Ivers, Mina Tadrous   +3 more
doaj   +1 more source

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

British Journal of Pharmacology, EarlyView.
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley   +1 more source

Glucagon-like Peptide-1 Receptor Agonists: Limitless Potential [PDF]

Doctor.Ru, 2020
T.Yu. Demidova, A.A. Kozhevnikov
openaire   +1 more source

Development of NAFLD‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation

Cell Proliferation, EarlyView.
Microporous array organ chips were integrated with commercially available well plates to develop organoid chip platforms, which enable modelling of hepatic physiology and non‐alcoholic fatty liver disease (NAFLD) pathogenesis, as well as evaluation of semaglutide therapeutics. ABSTRACT Progressive non‐alcoholic fatty liver disease (NAFLD) may culminate
Xiao‐yan You, Xiang‐yang Li, Hui Wang, Guo‐ping Zhao   +3 more
wiley   +1 more source

The Voice of a Disease: Why Food Noise Can No Longer Be Ignored!

Obesity, EarlyView.
Abdulhameed Alhazmi, Carel W. le Roux
wiley   +1 more source

Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Eloralintide (LY3841136) is a potent, long‐acting selective amylin receptor agonist currently under development for the treatment of obesity with once‐weekly subcutaneous dosing. Materials and Methods This 12‐week Phase 1, randomised, placebo‐controlled, participant‐ and investigator‐blinded, multiple ascending dose study evaluated the ...
Shobha Bhattachar, Lai San Tham, Beth Tidemann‐Miller, Hilda Ibriga, Hongchang Qu, Daniel A. Briere, Axel Haupt, Kieren J. Mather, Edward Pratt   +8 more
wiley   +1 more source

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide.
Xi Tan, Yuanjie Liang, Lin Xie, Joanna Harton, Cynthia Gutierrez, Chalak Muhammad, Caroline Swift, Adam de Havenon   +7 more
wiley   +1 more source

GLP‐1 receptor agonists and cardiovascular outcomes in Asian, Black or African American, and White populations: An updated meta‐analysis including the SOUL trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the cardiovascular efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in Asian, Black or African American, and White populations, and to assess whether the magnitude of cardiovascular risk reduction differs across these populations.
Masashi Hasebe, Chen‐Yang Su, Hisashi Kamido, Daisuke Yabe, Satoshi Yoshiji   +4 more
wiley   +1 more source